Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
NCT05187377Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of somatropin in Phelan-McDermid syndrome (PMS), Autism Spectrum Disorder (ASD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jan 2022; status: completed.
02
Drugs
somatropin
03
Conditions
Phelan-McDermid syndrome (PMS)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05187377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187377.